RESUMO
Background and study aims: The hemostatic powder TC-325 (Hemospray; Cook Medical, Winston-Salem, North Carolina, USA) has shown promising results in the treatment of upper gastrointestinal bleeding (UGIB) in expert centers in pilot studies. The aim of this study was to evaluate the feasibility and efficacy of TC-325 in a large prospective registry of use in routine practice. Patients and methods: The data of all patients treated with TC-325 were prospectively collected through a national registry. Outcomes were the immediate feasibility and efficacy of TC-325 application, as well as the rates of rebleeding at Day 8 and Day 30.âMultivariate analysis was performed to determine predictive factors of rebleeding. Results: A total of 202 patients were enrolled and 64 endoscopists participated from 20 centers. TC-325 was used as salvage therapy in 108 patients (53.5â%). The etiology of bleeding was an ulcer in 75 patients (37.1â%), tumor in 61 (30.2â%), postendoscopic therapy in 35 (17.3â%), or other in 31 (15.3â%). Application of the hemostatic powder was found to be very easy or easy in 31.7â% and 55.4â%, respectively. The immediate efficacy rate was 96.5â%. Recurrence of UGIB was noted at Day 8 and Day 30 in 26.7â% and 33.5â%, respectively. Predictive factors of recurrence at Day 8 were melena at initial presentation and use of TC-325 as salvage therapy. Conclusion: These multicenter data confirmed the high rate of immediate hemostasis, excellent feasibility, and good safety profile of TC-325, which could become the treatment of choice in bleeding tumors or postendoscopic bleeding but not in bleeding ulcers where randomized studies are needed. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02595853).
Assuntos
Hemorragia Gastrointestinal/terapia , Neoplasias Gastrointestinais/complicações , Hemostase Endoscópica , Hemostáticos/uso terapêutico , Minerais/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Endoscopia Gastrointestinal/efeitos adversos , Estudos de Viabilidade , Feminino , Hemorragia Gastrointestinal/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Úlcera Péptica/complicações , Pós/uso terapêutico , Estudos Prospectivos , Recidiva , Sistema de Registros , Fatores de RiscoRESUMO
INTRODUCTION: The transcriptional activity of the UGT1A1 gene is modulated by a variable number of repetitions of the dinucleotide (TA) within its promoter region. By comparison to the most common allele (TA)6 (UGT1A1*1), decreased activity is observed with increasing TA repetitions. The aim of this study was to determine whether the presence of the variant allele UGT1A1*28, harbouring seven TA repetitions, (TA)7, in the homozygous state, is associated with precancerous colonic lesions and/or with specific colorectal cancer characteristics. MATERIAL AND METHODS: All patients treated for colorectal cancer in a tertiary care centre, between January 2009 and December 2013, who had routine UGT1A1 genotyping for irinotecan dose-adjustment were included. Data were retrospectively collected. RESULTS: 292 patients were enrolled, including 23 UGT1A1*28/*28 homozygous (7.9%), 137 wild type homozygous (46.9%) and 132 heterozygous (45.2%). There were no significant differences in phenotypic colonic characteristics between homozygous and heterozygous patients carrying the UGT1A1*28 allele as compared to *1/*1 homozygous. Patients treated with aspirin were significantly more common in the UGT1A1*28/*28 homozygous group than in the other groups (7/23 (30.4%) compared to 22/269 (8.2%), pâ¯=â¯0.001). CONCLUSION: Dinucleotide polymorphism in the promoter region of the UGT1A1 gene is not associated with a specific colonic phenotype in patients with sporadic colorectal cancer.
Assuntos
Neoplasias Colorretais/genética , Glucuronosiltransferase/genética , Regiões Promotoras Genéticas , Adulto , Idoso , Idoso de 80 Anos ou mais , Alelos , Feminino , França , Predisposição Genética para Doença , Heterozigoto , Homozigoto , Humanos , Irinotecano , Masculino , Pessoa de Meia-Idade , Fenótipo , Polimorfismo Genético , Estudos Retrospectivos , Centros de Atenção TerciáriaRESUMO
OBJECTIVE: Carbohydrate-deficient transferrin has been proposed to be useful in evaluating alcohol consumption but there is no consensus on its use in routine practice. The aim of this retrospective study was to compare carbohydrate-deficient transferrin and gammaglutamyl transpeptidase assays for the evaluation of alcohol consumption. METHODS: Six hundred thirty-three outpatients attending one outpatient care center were included in this study. Patients were divided into five categories according to alcohol consumption: category 1 included non-weaned patients drinking more than 30 g/day for women and more than 50 g/day for men, category 2 included relapse patients, category 3 included moderate drinkers, category 4 included patients weaned less than one month, and category 5 included patients weaned more than one month. One experienced physician estimated alcohol intake from patient declarations during a face-to-face interview. RESULTS: Sensitivity of carbohydrate-deficient transferrin varied, depending on patient category, from 32% to 92% versus 41% to 72% for gamma-glutamyl transpeptidase. Specificity of carbohydrate-deficient transferrin varied from 71% to 96% versus 23% to 62% for gamma-glutamyl transpeptidase. After one month of abstinence, specificity of carbohydrate-deficient transferrin was 62% versus 19% for gamma-glutamyl transpeptidase. CONCLUSION: This study confirms that carbohydrate-deficient transferrin is more accurate in predicting alcohol consumption compared with gamma-glutamyl transpeptidase in alcoholic outpatients.